Alzheimer's Disease (AD)

Neurology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ABBV-916Phase 21 trial
Active Trials
NCT05291234Completed106Est. Nov 2025
Life Molecular Imaging
Life Molecular ImagingGermany - Berlin
1 program
1
[18F]MNI-815Phase 11 trial
Active Trials
NCT02531360CompletedEst. Aug 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieABBV-916
Life Molecular Imaging[18F]MNI-815

Clinical Trials (2)

Total enrollment: 106 patients across 2 trials

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

Start: Aug 2022Est. completion: Nov 2025106 patients
Phase 2Completed

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

Start: May 2015Est. completion: Aug 2016
Phase 1Completed

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space